Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04824586
Other study ID # Intraoperative Insulin
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 1, 2019
Est. completion date January 30, 2020

Study information

Verified date March 2021
Source The Hashemite University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study was to explore which insulin-based regimen is better, infusion or bolus regimen, for intraoperative management of glucose level for the diabetic patient at cardiac surgery. Secondary objectives include: comparing the relative amounts of insulin needed during the operation and subsequent cost impact and comparing potassium levels between groups. Ethical approval for the study was obtained from the Office for Research Ethics Committees at Hashemite University - Prince Hamza hospital. This study was a parallel-group, randomized, controlled trial with 1:1 allocation ratio. Participants: Adult diabetic patients, type 2, who were admitted to hospital for cardiac surgery. The intervention: Both patients in the infusion or bolus group received their dose of insulin, fast-acting human insulin (Actrapid®) was used. Setting: Patients were recruited at Prince Hamza hospital, Amman, Jordan. A tertiary care center specialized unit in cardiac surgery for diabetic patients. Outcomes monitoring: It was monitored six times as follows: preoperative induction measure, then glucose post heparin, and after that for 2 hours, glucose levels were monitored every 30 minutes. Insulin quantities were recorded as well to be used in secondary outcomes analysis. Randomization, allocation, and blinding During patient enrolment, concealed allocation to either infusion group or bolus group was guaranteed through the use of a closed envelope system prepared by an independent investigator. Block randomization with random block sizes, ensured allocation balance, and avoided selection bias by preventing allocation prediction. Researchers and physicians were blind to the block size sequence and randomization. Envelopes were unopened until completion of patient registration. Hospital staff who monitor glucose and those who administered insulin were blinded to the primary and secondary outcomes' measure.


Description:

The primary objective of the study was to explore which insulin-based regimen is better, infusion or bolus regimen, for intraoperative management of glucose level for the diabetic patient at cardiac surgery. Secondary objectives include: comparing the relative amounts of insulin needed during the operation and subsequent cost impact and comparing potassium levels between groups. Ethical approval and study registration Ethical approval for the study was obtained from the Office for Research Ethics Committees at Hashemite University - Prince Hamza hospital with reference number 2/1/2019/2020. Methods and Materials This study was a parallel-group, randomized, controlled trial with 1:1 allocation ratio. Participants Adult diabetic patients, type 2, who were admitted to hospital for cardiac surgery. In addition to signing the consent form, patients were recruited when they met the following criteria: >40 years old, patients who need the usual insulin according to insulin dosing guidelines, patients with pre-operation glucose level > 200 mg/dL and < 300 mg/dL. The following patients were excluded: Insulin sensitive patents (Age >70 years, Glomerular Filtration Rate (GFR) <45 ml/min, No history of Diabetes, Insulin resistance patients (Body Mass Index > 35 kg/m2, total daily insulin dose >80 units, Steroids > 20 mg prednisone daily, patients who at high risk of complications and or (those whom their operation was differed to be supervised by a specialized team). Patients who were unable to give written informed consent, who had ≥4 emergency admissions during the six months prior to the index admission. The intervention Both patients in the infusion or bolus group received their dose of insulin, fast-acting human insulin (Actrapid®) was used. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations. Setting Patients were recruited at Prince Hamza Hospital, Amman, Jordan. A tertiary care center specialized unit in cardiac surgery for diabetic patients. Diabetic patients who had booked cardiac surgery and met the criteria were invited to the study. Patients who accepted participation and signed the consent were recruited by well-trained research assistance, who was trained on an ethical standard and patient-centered approach. Primary and secondary outcomes In the present study, the primary outcome was the intraoperative level of glucose. It was monitored six times as follows: preoperative induction measure, then glucose post heparin, and after that for 2 hours, glucose levels were monitored every 30 minutes. Insulin quantities were recorded as well to be used in secondary outcomes analysis. Sample size To detect a difference of at least 25mg/dL between infusion and bolus groups (the standard deviation of the two groups is expected to be 35 mg/dL, i.e., the variance is 1225 mg/dL), the study will need to recruit and record full data for at least 31 patients in each group. Providing that significant level of confidence 95% and the power of 80%. n = (Zα/2+Zβ)2 *2*σ2 / d2. where Zα/2 is the critical value of the Normal distribution at α/2 (for a confidence level of 95%, α is 0.05, and the critical value is 1.96), Zβ is the critical value of the Normal distribution at β (for a power of 80%, β is 0.2, and the critical value is 0.84), σ2 is the population variance, and d is the difference needed to be detected. Statistical methods Standard independent-samples t-test or separate variances t-test (Welch t-test) was used to compare the results between the two arms of the study. General Linear Model, one-way repeated measures ANOVA was conducted to determine whether there was a statistically significant difference within groups. Cost analysis and cost-effectiveness were used for the pharmacoeconomic analysis. Incremental cost-effectiveness ratio (ICER) was calculated as the cost of insulin in the Infusion protocol minus the cost of insulin in the bolus protocol divided by drop-in glucose level by infusion - drop in glucose level by bolus). Randomization, allocation, and blinding During patient enrolment, concealed allocation to either infusion group or bolus group was guaranteed through the use of a closed envelope system prepared by an independent investigator. Block randomization with random block sizes, ensured allocation balance, and avoided selection bias by preventing allocation prediction. Researchers and physicians were blind to the block size sequence and randomization. Envelopes were unopened until completion of patient registration. Hospital staff who monitor glucose and those who administered insulin were blinded to the primary and secondary outcomes' measure.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date January 30, 2020
Est. primary completion date January 30, 2020
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Diabetic patients, type 2, who were admitted to hospital for cardiac surgery. - Patient above 40 years old, - Patients who need the usual insulin according to insulin dosing guidelines - Patients with pre-operation glucose level > 200 mg/dL and < 300 mg/dL. Exclusion Criteria: - Insulin sensitive patents (Age >70 years, Glomerular Filtration Rate (GFR) <45 ml/min, No history of Diabetes, Insulin resistance patients (Body Mass Index > 35 kg/m2, total daily insulin dose >80 units, Steroids > 20 mg prednisone daily, patients who at high risk of complications and or (those whom their operation was differed to be supervised by a specialized team). - Patients who were unable to give written informed consent. - Patients have =4 emergency admissions during the six months prior to the index admission.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fast-acting human insulin
Both patients in the infusion or bolus group received their dose of insulin. The protocol of the insulin regimen and its related details were carried out according to the standard recommendations in a hospital where the trial done.

Locations

Country Name City State
Jordan Prince Hamza Hospital Amman

Sponsors (1)

Lead Sponsor Collaborator
The Hashemite University

Country where clinical trial is conducted

Jordan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intraoperative level of glucose To explore which insulin-based regimen is better, infusion or bolus regimen, for intraoperative management of glucose level for the diabetic patient at cardiac surgery. Change from baseline glucose level (preoperative) at six hours intraoperative
Secondary Insulin quantities To compare the relative amounts of insulin needed during the operation and subsequent cost impact and comparing potassium levels between groups Change from baseline glucose level (preoperative) at six hours intraoperative
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A